[go: up one dir, main page]

WO2005033048A3 - Wnt pathway antagonists - Google Patents

Wnt pathway antagonists Download PDF

Info

Publication number
WO2005033048A3
WO2005033048A3 PCT/US2004/032148 US2004032148W WO2005033048A3 WO 2005033048 A3 WO2005033048 A3 WO 2005033048A3 US 2004032148 W US2004032148 W US 2004032148W WO 2005033048 A3 WO2005033048 A3 WO 2005033048A3
Authority
WO
WIPO (PCT)
Prior art keywords
wnt pathway
pathway antagonists
compounds
pathologies
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/032148
Other languages
French (fr)
Other versions
WO2005033048A2 (en
Inventor
Philip A Beachy
James K Chen
Randall K Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to US10/574,248 priority Critical patent/US7652043B2/en
Publication of WO2005033048A2 publication Critical patent/WO2005033048A2/en
Publication of WO2005033048A3 publication Critical patent/WO2005033048A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/22—Naphthotriazoles
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aromatic compounds for treating various diseases and pathologies are disclosed. The methods use of such compounds are also provided. Accordingly, the present invention makes available methods and compositions for inhibiting aberrant growth states in cells having Wnt receptors.
PCT/US2004/032148 2003-09-29 2004-09-29 Wnt pathway antagonists Ceased WO2005033048A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/574,248 US7652043B2 (en) 2004-09-29 2004-09-29 WNT pathway antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50716303P 2003-09-29 2003-09-29
US60/507,163 2003-09-29

Publications (2)

Publication Number Publication Date
WO2005033048A2 WO2005033048A2 (en) 2005-04-14
WO2005033048A3 true WO2005033048A3 (en) 2005-08-04

Family

ID=34421589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/032148 Ceased WO2005033048A2 (en) 2003-09-29 2004-09-29 Wnt pathway antagonists

Country Status (1)

Country Link
WO (1) WO2005033048A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105132357A (en) * 2015-07-29 2015-12-09 赫柏慧康生物科技无锡有限公司 Serum-free culture system for epidermal cell culture
US9730909B2 (en) 2010-03-19 2017-08-15 Boston Biomedical, Inc Methods for targeting cancer stem cells

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563813B2 (en) 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
WO2007030658A2 (en) 2005-09-08 2007-03-15 Children's Hospital Medical Center Compositions useful for and methods of modulating angiogenesis
WO2008021250A2 (en) * 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
PE20080932A1 (en) * 2006-11-10 2008-07-13 Wyeth Corp N-SUBSTITUTED PIPERIDINYL 4-ARYLSULFONAMIDES AS MODULATORS OF FRIZZLED-RELATED SECRETED PROTEIN 1 (SFRP-1)
WO2008137408A1 (en) * 2007-04-30 2008-11-13 Genentech, Inc. Pyrazole inhibitors of wnt signaling
SI2194783T1 (en) * 2007-08-10 2017-12-29 Vm Discovery, Inc. Compositions and methods for apoptosis modulators
US9745278B2 (en) * 2007-09-10 2017-08-29 Boston Biomedical, Inc. Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2011041731A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Method of inhibiting bcl-2-related survival proteins
WO2011041737A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Gain-of-function bcl-2 inhibitors
KR20150139955A (en) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 2-acetylnaphtho[2,3-b]furan-4,9-dione for use on treating cancer
WO2015131035A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
JP6728061B2 (en) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Tetrahydroquinoline sulfonamide and related compounds for use as RORγ agonists and treatment of diseases
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
HK1253734A1 (en) 2015-06-11 2019-06-28 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
JP7106563B2 (en) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Naphthofuran derivatives, their preparation and methods of use
JP2020520923A (en) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド Methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378360A (en) * 1980-04-22 1983-03-29 Beecham Group Limited 6-{3-[4-(Substituted benzyl)-1-piperazinyl]propyloxy}-4,9-dihydro-4,9-dioxo-1H-naphtho[2,3-d-]-v
US4424361A (en) * 1980-01-23 1984-01-03 Beecham Group Limited Process for preparing polycyclic triazoles used to inhibit allergic responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424361A (en) * 1980-01-23 1984-01-03 Beecham Group Limited Process for preparing polycyclic triazoles used to inhibit allergic responses
US4378360A (en) * 1980-04-22 1983-03-29 Beecham Group Limited 6-{3-[4-(Substituted benzyl)-1-piperazinyl]propyloxy}-4,9-dihydro-4,9-dioxo-1H-naphtho[2,3-d-]-v

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730909B2 (en) 2010-03-19 2017-08-15 Boston Biomedical, Inc Methods for targeting cancer stem cells
CN105132357A (en) * 2015-07-29 2015-12-09 赫柏慧康生物科技无锡有限公司 Serum-free culture system for epidermal cell culture

Also Published As

Publication number Publication date
WO2005033048A2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
WO2005033048A3 (en) Wnt pathway antagonists
WO2005033288A3 (en) Hedgehog pathway antagonists
WO2006021881A3 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2006021884A3 (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
WO2007079164A3 (en) Protein kinase inhibitors
NL1025071A1 (en) Compounds for the treatment of abnormal cell growth.
EP1583821A4 (en) Methods and compositions for treating urological disorders using 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 76
WO2006133426A3 (en) Compositions and methods for inhibition of the jak pathway
WO2006050109A3 (en) Novel kinase inhibitors
WO2006073939A3 (en) 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
WO2005046603A3 (en) Pyridine compounds
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
EP1705989B8 (en) Substituted arylpyrazoles as parasiticidal agents
WO2007050587A3 (en) Therapeutic compositions and methods
JO2578B1 (en) 228 Benzimidazole Thiophene Compounds
WO2004043379A3 (en) Chemical compounds
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
WO2004087066A3 (en) Hif-1 inhibitors
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
AR028248A1 (en) NEW COMPOUNDS 2,3,4,5-TETRAHIDRO-1H- (1,4) DIAZEPINO (1,7-A) INDOL
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
WO2004087652A3 (en) Imidazotriazine compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10574248

Country of ref document: US

Ref document number: 2007219257

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10574248

Country of ref document: US